G CEO Kalra exercises 40,000 options at $27.65 and sells 55,000 shares
Rhea-AI Filing Summary
Insider transactions by Genpact Ltd director and CEO Balkrishan Kalra. On 09/11/2025 Mr. Kalra sold 15,000 common shares at a weighted-average price of approximately $43.39 and sold 40,000 common shares at a weighted-average price of approximately $43.35, reducing his reported beneficial ownership to 295,246 shares. On the same date he acquired 40,000 common shares by exercising employee stock options at a $27.65 exercise price, bringing his beneficial ownership to 335,246 shares before the net sales shown. The Form 4 shows the option originally vested in two tranches (50% on 01/10/2019 and the remainder on 01/10/2021) and lists 40,000 underlying shares exercised with 2,800 derivative securities remaining reported as beneficially owned. Transactions were signed by an attorney-in-fact on 09/15/2025.
Positive
- Transparent disclosure of option vesting dates and weighted-average sale price ranges with offer to provide per-share sale prices on request
- Exercise of employee stock options at a reported $27.65 price, converting compensation into equity
Negative
- Insider sold 55,000 shares on the same day as the exercise, which reduced reported beneficial ownership from 335,246 to 295,246 shares
Insights
TL;DR: Insider exercised 40k options at $27.65 and sold 55k shares at ~$43.35–$43.39 on 09/11/2025.
The filing documents a contemporaneous option exercise and open-market sales by a named executive and director. Exercising 40,000 options at $27.65 converted employee stock options into common shares, followed by sales totaling 55,000 shares at weighted-average prices around $43.35–$43.39. The report shows reported beneficial ownership levels of 335,246 and 295,246 shares after the respective acquisition and sales entries. These are routine Section 16 transactions: the exercise captures intrinsic value between exercise price and sale price, and the Form 4 discloses the weighted-average sale price ranges per the explanation. No other compensatory or extraordinary terms are disclosed in this filing.
TL;DR: Transactions are disclosed cleanly; vesting history is provided, no governance red flags shown.
The filing identifies the reporting person as both President & CEO and a director, and it documents vesting dates for the option grant (50% vested 01/10/2019, remainder 01/10/2021). The Form 4 was executed by an attorney-in-fact and includes weighted-average price ranges for the sales, with an explicit offer to provide per-share sale price breakdown on request. Nothing in the form indicates undisclosed related-party transfers or material omissions within the scope of the reported transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
| Sale | Common Shares | 15,000 | $43.39 | $651K |
| Exercise | Common Shares | 40,000 | $27.65 | $1.11M |
| Sale | Common Shares | 40,000 | $43.35 | $1.73M |
Footnotes (1)
- The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $43.39 to $43.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $43.29 to $43.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option vested 50% on January 10, 2019 and the remainder on January 10, 2021.
